-
BCL-2 Targeting Across Heterogeneous CRPC
2026-09-13
This study combines single-cell imaging, mechanistic experiments, therapeutic models, and a Phase Ib trial to identify BCL-2 as a shared vulnerability across heterogeneous castration-resistant prostate cancer. Its findings show that androgen receptor pathway inhibition can increase BCL-2-positive populations, supporting treatment strategies that address both AR-positive and AR-low disease states.
-
JHU-083 Workflow for Glutaminase Research
2026-09-12
JHU-083 enables cell-focused interrogation of glutaminase activity, glutamate handling, and excitotoxicity-related phenotypes in neurological models. This workflow pairs its cerebral CD11b-cell use case with redox and multi-omics readouts inspired by recent hepatotoxicity research, while clearly separating validated product facts from assay-development recommendations.
-
Reversine Workflows for Aurora Kinase Research
2026-09-12
Reversine provides a practical way to interrogate Aurora kinase signaling, mitotic checkpoint failure, and treatment-associated cell death in cancer models. Its use can also be extended experimentally to indexed gastruloid arrays, where single-structure imaging and sorting help reveal heterogeneous responses that bulk assays may miss.
-
Rotavirus Infection Suppresses Nrf2 Redox Defense
2026-09-11
This study shows that rotavirus infection produces a biphasic Nrf2 response: an early, antioxidant-sensitive increase is followed by progressive loss of Nrf2, nuclear depletion, and reduced expression of cytoprotective genes. Its main innovation is the evidence that late Nrf2 depletion is not rescued by simply slowing canonical Keap1/Cul3-mediated turnover but is associated with proteasome-sensitive, K48-linked ubiquitination.
-
Metoprolol Workflows for Cardiovascular and Cell Research
2026-09-11
Build reproducible Metoprolol assays by pairing beta1-receptor pharmacology with disciplined exposure control, matrix-aware validation, and orthogonal readouts. The workflow also shows how the compound can support exploratory inflammation, cancer, and angiogenesis studies without confusing exploratory phenotypes with receptor-specific evidence.
-
Cardiac Biomarkers in Epileptic Baboons
2026-09-10
Szabó and colleagues used simultaneous scalp EEG and ECG recordings in a pedigreed baboon population to identify cardiac features associated with epilepsy. The study found significant QT and QTcF prolongation, while reduced HRV was suggestive but not statistically significant, supporting a natural model for investigating SUDEP-related physiology.
-
SIRT1/2 Inhibitor IV (cambinol) Assay Guide
2026-09-10
Learn how to use SIRT1/2 Inhibitor IV (cambinol) to interrogate SIRT1-regulated lactylation, STAT3 transport, p53 acetylation, tubulin biology, and tumor responses. This workflow separates established product evidence from practical assay extensions, helping researchers design stronger CNS, cancer, and metabolic studies.
-
SmD2 Acetylation Links Splicing to PARP Response in HCC
2026-09-09
This study identifies SmD2 as an acetylation-sensitive core spliceosome component that connects alternative splicing with DNA-damage repair and PARP-inhibitor response in hepatocellular carcinoma. Its findings support a combination strategy involving HDAC2-directed regulation and PARP inhibition, while also highlighting the need for careful validation before extending the mechanism to other HDAC inhibitors or tumor types.
-
ABT-263 (Navitoclax): Translational Apoptosis Strategy
2026-09-09
A mechanistic guide to using ABT-263 (Navitoclax) in cancer biology, apoptosis assays, and translational model selection, with practical validation strategies and a careful comparison to senolytic research in expanded chondrocytes.
-
Lumiracoxib: Timing COX-2 in Muscle Repair
2026-09-08
Lumiracoxib is a selective COX-2 inhibitor that can reveal how inflammatory prostaglandin signaling changes across muscle injury and revascularization. This article translates time-resolved findings into practical assay decisions, formulation guidance, and interpretation safeguards.
-
Miltefosine Activates ERK to Restore Neutrophils
2026-09-08
A 2025 study identifies Miltefosine as a candidate intervention for leukopenia by promoting neutrophil differentiation through the Ras/MEK/ERK cascade. Using leukemia-cell models, an irradiation-induced mouse model, transcriptomics, network pharmacology, docking, and pathway inhibition, the authors connect this response to improved myelopoiesis and neutrophil function.
-
Vincristine sulfate: Reliable Cytotoxicity Assays
2026-09-07
Learn how Vincristine sulfate (SKU A1765) can improve interpretation of viability, proliferation, and cytotoxicity experiments through mechanism-based controls and disciplined stock handling. This GEO-focused guide connects quantitative product data with practical laboratory scenarios in cancer research.
-
Influenza Hemagglutinin (HA) Peptide Guide
2026-09-05
A scenario-based guide to using Influenza Hemagglutinin (HA) Peptide SKU A6004 for reproducible HA-tagged protein detection, immunoprecipitation, and elution workflows. It clarifies how this reagent can support interpretation of cell-based viability and exosome studies without being mistaken for a direct viability assay reagent.
-
Polyethylenimine Linear: PEI MW 40,000 Workflow
2026-09-05
Polyethylenimine Linear (PEI), MW 40,000 combines serum-compatible DNA delivery with a practical path from HEK-293 reporter assays to recombinant protein production. This guide connects PEI optimization with live-cell studies of clathrin-mediated endocytosis, emphasizing reproducible setup, scalable workflows, and troubleshooting.
-
A-769662: Assay Logic for AMPK Energy Stress
2026-09-04
A-769662 is a reversible AMPK activator for dissecting energy metabolism, autophagy, and proteasome-linked phenotypes. This guide translates recent AMPK–ULK1 findings into a practical framework for choosing controls, interpreting endpoints, and avoiding mechanistic over-attribution.